Summary: There are few data regarding the use of enoxaparin in children undergoing myelosuppressive therapy for malignancies even though thrombosis is a known risk in pediatric patients with malignancies. Low-molecular-weight heparin such as enoxaparin has become widely used in adult patients with thrombosis. The purpose of this study was to review the utilization of low-molecular-weight heparin, enoxaparin (Lovenox), in children with cancer at our institution who had thrombosis while undergoing myelosuppressive chemotherapy. In particular we were interested in the efficacy of enoxaparin in these patients, and in whether these children were able to continue their chemotherapy without adjustment or interruption secondary to bleeding complications. We conducted a retrospective review from 1999 through April 1, 2004 . Seven patients (4-17 years of age) were identified. Diagnosis included B-precursor acute lymphoblastic leukemia (ALL) (n=three), T-ALL, Hodgkin's disease, anaplastic large cell lymphoma, and rhabdomyosarcoma (n=one each). Six patients had a deep vein thrombus (DVT) or clot of the vena cava. One of these six patients also had a pulmonary embolus. One patient presented with manifestations of a unilateral cerebral vascular accident without evidence of DVT. Most patients were screened for known hypercoaguable abnormalities. Treatment was enoxaparin, 1-1.5 mg/kg/dose twice daily to maintain a heparin anti-Xa level of 0.5-1.5 IU/mL till clot resolution. The dose was then decreased to daily for a total of 3-6 months of therapy. All patients had resolution of their thrombosis within 1-2 months of initiation of enoxaparin, and none required delays or dose reduction of their chemotherapy regimens while on anticoagulation, though some were supported by blood and platelet transfusions. Enoxaparin was safely administered to this series of seven patients for thrombotic complications in children undergoing cancer chemotherapy. Key Words: enoxaparin -DVT -pediatric malignancy.
However, there are few data regarding the use of enoxaparin in children undergoing myelosuppressive therapy for malignancies. The purpose of this study was to review the utilization of lowmolecular-weight heparin, enoxaparin (Lovenox), in children with cancer at this institution who had thrombosis while undergoing myelosuppressive chemotherapy. In particular we were interested in the ability of enoxaparin to prevent thrombus extension while the natural process of thrombolysis led to resolution of the thrombus, and in whether these children were able to continue their chemotherapy without adjustment or interruption secondary to bleeding complications.
METHODS
IRB approval to review charts was obtained and then a chart review from 1999 through April 1, 2004, was performed. Seven patients with various malignancies were found to have a vascular thrombotic event.
RESULTS
A summary of the patients data is located in Table 1 . The age range was 4-17 years. The diagnosis included B-precursor acute lymphoblastic leukemia (ALL) (n=three), T-ALL, Hodgkin's disease, anaplastic large cell lymphoma, and rhabdomyosarcoma (n=one each). Six patients de-veloped a deep vein thrombus (DVT) or clot of the vena cava. One of these six patients also had a pulmonary embolus. One patient presented with manifestations of a unilateral cerebral vascular accident without evidence of a DVT. Ultrasound and computed tomography/magnetic resonance imaging (CT/MRI) were performed on patients when appropriate. Patients were screened when possible for thrombophilia including protein C, protein S, AT III, factor V Leiden mutation, prothrombin 20210A mutation, and lupus anticoagulant. A summary of the test results is located in Table 2 .
CASE REPORTS
Patient 1: A 16-year-old male diagnosed with T-cell ALL November 22, 2001. The patient was treated along the guidelines of POG 9404, which utilized L-asparaginase, prednisone, doxorubicin, vincristine, low-and high-dose methotrexate, and 6-mercaptopurine during induction and consolidation, followed by vincristine, prednisone, methotrexate, and 6-mercaptopurine during maintenance. Fifty-four weeks after starting therapy (seven months after the last dose of L-asparaginase) during maintenance chemotherapy, he developed a pulmonary embolus documented by spiral CT and clinical symptoms of oxygen requirement and chest pain. The patient was treated with enoxaparin to maintain heparin anti-Xa activity between 0.5 and 1.5 U/mL. The patient tolerated this therapy without complication and was able to receive his chemotherapy without adjustment for bleeding complications. His laboratory nadirs included a platelet count of 157 K/uL, white blood cells (WBC) 2.51 K/uL, and an absolute neutrophil count (ANC) of 1210. He required two red blood cell (RBC) transfusions during this time for chemotherapy-associated anemia.
Patient 2: A 12-year-old female diagnosed with anaplastic large cell lymphoma of the distal femur in May 2002. She was treated following the guidelines of POG 9315 using vincristine and doxorubicin till maximum dose given, then methotrexate, prednisone, and 6-mercaptopurine. Her leg was in an immobilizer and she did not receive any L-asparaginase. She developed a DVT of the leg two months after placement of the immobilizer. She was started on Lovenox and continued her therapy without interruption or adjustment during the six months of anticoagulation. Her laboratory nadirs included a platelet count of 104 K/µL, WBC 2.15 K/µL, and an ANC 550. The patient did not require any transfusions during this time period.
Patient 3: A 17-year-old male diagnosed with ALL and started on four-drug induction of vincristine, prednisone, daunomycin, and l-asparaginase October 22, 1999. He developed thrombosis of the left brachial vein November 12, 1999, week three of induction. He was treated with Lovenox, completed his induction and high-risk ALL therapy without further complication or adjustment for bleeding. His laboratory nadirs included a platelet count of 10 K/µL, WBC 0.15 K/µL, and an ANC of 0. He was transfused with RBCs and platelets during periods of severe ane-mia or thrombocytopenia (hemoglobin 7.5 gm/dL or platelets 20 K/uL).
Patient 4: A 12-year-old male diagnosed with Hodgkin's disease November 5, 2003 , and presented at diagnosis with thrombosis of the iliac vein thought to be secondary to mass affect by the pelvic lymphomatous mass. He was started on Lovenox and treated with myelosuppressive chemotherapy (bleomycin, cyclophosphamide, doxorubicin, etoposide, and vincristine) without interruption. His lymphoma resolved as well as the thrombosis. His laboratory nadirs included a platelet count of 180 K/µL, WBC 2.8 K/µL, and an ANC of 360.
Patient 5: A 12-year-old male diagnosed with ALL April 15, 2003, and treated with three-drug induction consisting of vincristine, prednisose, and l-asparaginase. While receiving intensive consolidation with combinations of ARA-C, daunomycin, Tenoposide, methotrexate, 6-mercaptopurine, prednisose, and PEG-asparaginase, he received Peg-asparaginase and two days later presented with a clinical stroke documented by ischemic changes seen on an MRI of the brain. He was started on Lovenox immediately. Laboratory nadirs were platelet count of 60 K/µL, WBC 1.09 K/µL, and an ANC of 620. The patient received platelet transfusions if the platelet count fell below 100 K/µL. Not done: Tests were not performed as thrombus was believed to be secondary to mass compression of the vessel or in the case of #2, she was in a knee immobilizer after surgery.
therapy without interruption or complication. Laboratory nadirs included platelet count 45 K/uL, WBC 1.4 K/uL, and an ANC of 20. He was transfused with platelets. Patient 7: A five-year-old male presented with pelvic rhabdomyosarcoma with vascular compression at diagnosis, radiographic documentation of a thrombus in the inferior vena cava and both common iliac veins on March 3, 2003 . He was started on enoxaparin and maintained the heparin anti-Xa at .5-1.5 U/mL. He was treated with vincristine, actinomycin, and cyclophosphamide without interruption or alteration of the chemotherapy while on enoxaparin.
Resolution of thrombi was documented by the tool used to demonstrate the initial lesion, such as Doppler flow ultrasonography, MRI, or CT. This radiographic reevaluation was usually performed between 4 and 6 weeks after the beginning of anticoagulation, and repeated every 4 weeks till clot resolution was confirmed. All the patient's thrombi had resolved by the eight-week evaluation.
DISCUSSION
While adult patients with malignancies and deep vein thrombosis (DVT) are at an increased risk of recurrent DVT even while on anticoagulant therapy, the same risk is not known in pediatric patients (7, 10, 11) . Reports in adult patients suggest that patients with malignancies have increased risk of bleeding while receiving anticoagulant therapy (4, 12) . Prandoni et al (13) reported on a prospective study in patients with thrombosis and cancer to determine risk of recurrent thrombotic complications. Of the 842 patients followed up, 181 had a malignancy and thrombus. Of the 181 patients, the cumulative incidence of recurrent thromboembolus was 20.7% compared to 6.8% in patients without cancer. Risk of bleeding was high in the cancer group compared to the noncancer group, 12.4% vs. 4.9% (13) . The incidence of thrombosis in the pediatric population has been reported to vary from 0.7 to 5.1 per 100,000 children (14) . This incidence increases with the presence of a central line (1, 5, 15, 16) .
Hull et al (17) assessed the need for long-term treatment and prophylaxis of adult patients with proximal venous thrombosis and concluded that three months of therapy was necessary to prevent recurrent venous thromboembolism. Since then other studies have raised the issue of increased or prolonged risk of thromboembolism in patients with malignancies (4, 12, 18) . These studies have been performed in adult patient populations. The adult patients evaluated were found to have an increased risk of bleeding if treated with warfarin compared to LMWH. Levine (18) also noted in the adult population a decrease in recurrent DVTs when treated with LMWH. The use of low-molecular-weight heparin has increased dramatically as people find it simpler to control the therapeutic levels compared to the use of oral coumadin (9) . The effective dose of oral anticoagulants can vary with changes in diet, compliance with medication, narrow dose range, and potential interaction with other medications especially for children with malignancies. Because of the potential problem with regulating coumadin dosing, we elected to treat our patients with thrombosis using LMWH. Once a therapeutic level was established by measuring the heparin anti-Xa activity, the dose was maintained till the thrombus had resolved, then the patient was continued on a maintenance program for a minimum of three months. After the course of maintenance therapy, they were reevaluated and considered for discontinuation of anticoagulation therapy.
We were able to maintain anticoagulation while simultaneously administering therapeutic chemotherapy for the complex and diverse group of patients. Although this is a small number of patients and the diagnosis and treatment plans varied, the therapy was potentially myelosuppressive. The platelet nadir while on anticoagulation therapy was 15 K/µL and the ANC nadir was 0. Anticoagulation was not altered owing to bleeding. Some patients required transfusions of either pRBCs or platelets for chemotherapy-induced anemia or thrombocytopenia. Our trigger of pRBC transfusions is usually 7.5 gm/dL. The trigger for platelet transfusions is not fixed as it is dependent on age, the use of potentially myelosuppressive chemotherapy, and past history of bleeding events.
In conclusion, LMWH, in particular enoxaparin, can be administered safely to children receiving chemotherapy while minimizing the risk of complications of the existing thrombus. This chart review was for patients receiving chemotherapy and developing a thrombosis during this five-year interval. Patients who developed thrombosis without a prior or existing diagnosis of benign or malignant disease and not receiving chemotherapy were excluded from this chart review. Further studies to document minimally necessary dosing and duration of therapy are necessary.
